 |
|
|
| |
Sustained Efficacy with Low and Similar Rates of Virologic Failures in Second Year Observed with Rilpivirine (RPV) versus Efavirenz (EFV) plus Emtricitabine/Tenofovir DF (FTC/TDF) in Treatment-Naïve, HIV-1 Infected Adults - Pooled 96-Week ECHO and THRIVE Analysis
|
| |
| |
Reported by Jules Levin, EACS, European AIDS Conference Belgrade Oct 12-15 2011
M Nelson,1 G Behrens,2 C Cohen,3 S Vanveggel,4 K Boven,5
L Zhong,6 B Guyer,6 and SK Chuck6
1Chelsea & Westminster Hospital, London, United Kingdom;
2Hanover Medical School, Hanover, Germany; 3Community Research Initiative of New England, Boston, United States; 4Tibotec BVBA, Beerse, Belgium; 5Tibotec Inc, Titusville, United States; 6Gilead Sciences, Inc., Foster City, United States
1. FDA Approval of Edurant (rilpivirine) a new NNRTI) for the treatment ...
www.natap.org/2011/newsUpdates/052311_08.htm
May 20, 2011 - In TMC278 C209, the BR was fixed to the nucleoside (tide) reverse ... For subjects with baseline plasma viral load ≥ 100000 copies/mL
2. Pooled Week 48 efficacy and safety results from ECHO and THRIVE ...
www.natap.org/2010/IAS/IAS_57.htm -
Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz
3. Pooled Week 96 efficacy, resistance and safety results from the ...
www.natap.org/2011/IAS/IAS_15.htm
by CJ Cohen Jul 20, 2011 - ECHO (TMC278-C209, NCT00540449)1 and THRIVE (TMC278-C215, NCT00543725)2 were global, randomised, double-blind
|
| |
|
|
|
|
|
